SK bioscience Inks $260M Deal with Colombia’s VECOL for Local Vaccine Production
Event summary
- SK bioscience has signed a technology transfer agreement with Colombia’s state-owned VECOL to manufacture SKYVaricella, a varicella vaccine, as part of Colombia’s $260M vaccine localization initiative.
- The deal follows a four-year review process where SK bioscience was selected for its WHO prequalified vaccine portfolio and global manufacturing capabilities.
- SK bioscience will provide technology and know-how for local manufacturing, while VECOL will oversee facility establishment and regulatory approvals.
- The partnership aims to strengthen Colombia’s vaccine self-sufficiency and public health preparedness, with potential expansion into additional vaccine products.
The big picture
The deal underscores the growing demand for local vaccine manufacturing capabilities in Latin America, driven by post-pandemic supply chain resilience concerns. Colombia’s $260M initiative reflects a broader trend of governments investing in health sovereignty to reduce external dependencies. SK bioscience’s selection highlights its competitive edge in WHO prequalified vaccines and global manufacturing expertise, positioning it as a key player in regional vaccine production.
What we're watching
- Regional Expansion
- Whether SK bioscience can leverage this partnership as a foothold for broader Latin American expansion, establishing an integrated regional vaccine production network.
- Execution Risk
- The pace at which SK bioscience and VECOL can establish local manufacturing capabilities and secure regulatory approvals for SKYVaricella.
- Portfolio Expansion
- How quickly SK bioscience can expand the cooperation into additional vaccine products beyond SKYVaricella.
Related topics